CRTX - Cortexyme, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
39.50
+4.57 (+13.08%)
As of 12:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close34.93
Open36.65
Bid38.08 x 1200
Ask39.75 x 1100
Day's range35.78 - 42.19
52-week range19.35 - 73.84
Volume52,643
Avg. volume153,573
Market cap1.161B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.94
Earnings date16 Mar 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est79.60
  • Business Wire

    Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced new data supporting the ability of the pathogen Porphyromonas gingivalis to invade brain cells and trigger characteristic Alzheimer’s pathology including synaptic loss, ultrastructural changes, and inflammation. The data is being presented this week as part of the Advances in Alzheimer’s and Parkinson’s Disease (AAT-AD/PD) Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5.

  • Business Wire

    Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced financial results for the fourth quarter and full year 2019 and provided an update on its business.

  • Business Wire

    Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients

    Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease has reached 300 patients toward the study’s previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of COR388, Cortexyme’s lead investigational medicine, in patients with mild to moderate Alzheimer’s disease. GAIN’s protocol includes an interim analysis for overwhelming efficacy on its co-primary cognitive and functional endpoints after 300 patients reach six months of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results from the GAIN Trial’s final analysis, to be performed once all study subjects complete one year of treatment, are expected in Q4 2021.

  • Business Wire

    Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease

    Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s disease (AD). The company conducted a Type C meeting with the FDA gathering agreement and feedback on development plans through NDA, including the Phase 2/3 GAIN Trial statistical analysis plan, metabolite characterization, nonclinical studies, population pharmacokinetics, and drug-drug interaction studies.

  • Business Wire

    Cortexyme Announces Closing of $125 Million Private Placement

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 shares of common stock for a purchase price of $50.00 per share, resulting in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement primarily to advance clinical development, as well as for general corporate purposes.

  • Business Wire

    Cortexyme Announces $125 Million Private Placement

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company’s Board of Directors in connection with a private placement of its common stock. The transaction is expected to result in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company plans to use the net proceeds from the private placement primarily to advance clinical development, as well as for general corporate purposes.

  • Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber
    Zacks

    The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

    The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

  • 5 Hottest IPOs of 2019
    Zacks

    5 Hottest IPOs of 2019

    2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.

  • Fiverr Languishes Below IPO Price as First Chance to Sell Nears
    Bloomberg

    Fiverr Languishes Below IPO Price as First Chance to Sell Nears

    (Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
    Zacks

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

  • 4 Best-Performing IPOs So Far in 2019
    Zacks

    4 Best-Performing IPOs So Far in 2019

    Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

  • Top Ranked Momentum Stocks to Buy for October 9th
    Zacks

    Top Ranked Momentum Stocks to Buy for October 9th

    Top Ranked Momentum Stocks to Buy for October 9th

  • Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Top Ranked Momentum Stocks to Buy for September 23rd
    Zacks

    Top Ranked Momentum Stocks to Buy for September 23rd

    Top Ranked Momentum Stocks to Buy for September 23rd

  • What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own?

    The big shareholder groups in Cortexyme, Inc. (NASDAQ:CRTX) have power over the company. Generally speaking, as a...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more